Advanced search
Publication Cover
Postgraduate Medicine Volume 129, 2017 - Issue 4
Submit an article Journal homepage
448
Views
10
CrossRef citations to date
0
Altmetric
Clinical Features - Review

Biosimilar biologic drugs: a new frontier in medical care

Daniel M. GeynismanFox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USACorrespondence[email protected]
View further author information
,
Guillermo De VelascoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, SpainView further author information
,
K. Lea SewellBiotechnology Clinical Development, Pfizer Inc, Cambridge, MA, USAView further author information
&
Ira JacobsGlobal Established Pharma Medicines Development Group, Pfizer Inc, New York, NY, USAView further author information
Pages 460-470 | Received 23 Jan 2017, Accepted 22 Mar 2017, Published online: 03 Apr 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto & Steven Simoens. (2020) Economic evaluation of biosimilars for reimbursement purposes – what, when, how?. Journal of Market Access & Health Policy 8:1.
Read now

Articles from other publishers (9)

Zenglei Hu, Jianing Feng, Jing Deng, Yanyan Zhang, Xiaozheng He, Jiao Hu, Xiaoquan Wang, Shunlin Hu, Xiaowen Liu & Xiufan Liu. (2022) Delivery of Fc-fusion Protein by a Recombinant Newcastle Disease Virus Vector. Applied Biochemistry and Biotechnology 195:3, pages 2077-2092.
Crossref
Benjamin Punz, Litty Johnson, Mark Geppert, Hieu-Hoa Dang, Jutta Horejs-Hoeck, Albert Duschl & Martin Himly. (2022) Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms. Pharmaceutics 14:5, pages 1103.
Crossref
Tomas Tesar, Peter Golias, Zuzana Kobliskova, Martin Wawruch, Paweł Kawalec & András Inotai. (2020) Potential Cost-Savings From the Use of the Biosimilars in Slovakia. Frontiers in Public Health 8.
Crossref
Tomas Tesar, Peter Golias, András Inotai, Paweł Kawalec & Martin Wawruch. (2019) The impact of implemented regulations on biosimilars in Slovakia. Health Policy and Technology 8:4, pages 408-413.
Crossref
Seung-Mi Lee, Jae-Ho Jung, David Suh, Yu-Seon Jung, Seung-Lai Yoo, Dong-Won Kim, Ji-An Kim & Dong-Churl Suh. (2019) Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries. BioDrugs 33:4, pages 423-436.
Crossref
Evelien Moorkens, Steven Simoens, Per Troein, Paul Declerck, Arnold G. Vulto & Isabelle Huys. (2019) Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting. BioDrugs 33:3, pages 299-306.
Crossref
Evelien Moorkens, Steven Simoens, Per Troein, Paul Declerck, Arnold G. Vulto & Isabelle Huys. (2019) Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting. BioDrugs 33:3, pages 285-297.
Crossref
Maria Kamusheva, Manoela Manova, Alexandra T. Savova, Guenka I. Petrova, Konstantin Mitov, András Harsányi, Zoltán Kaló, Kristóf Márky, Pawel Kawalec, Bistra Angelovska, Dragana Lakić, Tomas Tesar, Pero Draganic, Mary Geitona, Magdalini Hatzikou, Marian S. Paveliu & Agnes Männik. (2018) Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Frontiers in Pharmacology 9.
Crossref
Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E. Martikainen, Gisbert W. Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon & Steven Simoens. (2017) Policies for biosimilar uptake in Europe: An overview. PLOS ONE 12:12, pages e0190147.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.